CELLECTIS
Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.
CELLECTIS
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
1999-12-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.cellectis.com
Total Employee:
51+
Status:
Active
Contact:
+1 (347) 752-4044
Total Funding:
181.35 M USD
Technology used in webpage:
Domain Not Resolving ReCAPTCHA ReCAPTCHA V2 Apple Whitelist
Similar Organizations
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
CeNeS Pharmaceuticals
CeNeS Pharmaceuticals is a biopharmaceutical company that develops and commercializes.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
IntelliHep
IntelliHep is a spin-out company developing novel drugs for Alzheimers disease and cancer.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company with one approved product.
Urovant Sciences
Urovant Sciences is a global biopharmaceutical company focused on developing novel therapies for urologic conditions.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2011-09-15 | Cellartis | Cellartis acquired by Cellectis | N/A |
| 2010-09-09 | Cyto Pulse Sciences | Cyto Pulse Sciences acquired by Cellectis | 2.2 M USD |
Investors List
4BIO Capital
4BIO Capital investment in Post-IPO Equity - Cellectis
Andera Partners
Andera Partners investment in Series C - Cellectis
BankInvest Biomedical Venture
BankInvest Biomedical Venture investment in Series C - Cellectis
ODYSSEE VENTURE
ODYSSEE VENTURE investment in Series C - Cellectis
Idinvest Partners
Idinvest Partners investment in Series C - Cellectis
Andera Partners
Andera Partners investment in Series B - Cellectis
Idinvest Partners
Idinvest Partners investment in Series B - Cellectis
BankInvest Biomedical Venture
BankInvest Biomedical Venture investment in Series B - Cellectis
ODYSSEE VENTURE
ODYSSEE VENTURE investment in Series B - Cellectis
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-10 | Cellectis Appoints Bing Wang, PhD, MBA as Chief Financial Officer |
Official Site Inspections
http://www.cellectis.com Semrush global rank: 2.63 M Semrush visits lastest month: 6.52 K
- Host name: 178.16.164.60
- IP address: 178.16.164.60
- Location: Paris France
- Latitude: 48.8543
- Longitude: 2.3527
- Timezone: Europe/Paris
- Postal: 75011
More informations about "Cellectis"
Home | Cellectis
Cellectis leverages its leadership in gene editing through its flagship technology, TALEN ®, which allows the company to create CAR T therapies to bring new hope to cancer patients through broadly available, off-the-shelf therapies.TALEN ® has been successfully used in the clinic to solve key challenges with allogeneic CAR T including protection from Graft vs. Host Disease, …See details»
Corporate Governance - Cellectis
Kyung Nam-Wortman joined Cellectis in November 2020 as Executive Vice President, Chief Human Resources Officer. Ms. Nam-Wortman’s role is to ensure that the Company advances …See details»
About - Cellectis
Cellectis is committed to good corporate governance, which promotes the long-term interests of shareholders, strengthens the Board of Directors and management accountability and helps …See details»
Cellectis - Wikipedia
Cellectis was founded by André Choulika in 1999. It built up a successful business based on the use of Meganuclease in genome engineering. Cellectis became a publicly traded company in 2007, and raised €21.2 million in a stock offering on Euronext. In 2010, it acquired Cyto Pulse, which had developed a new electroporation technology, and in 2011 it paid €28 million for Cellartis, a Swedish biotechnology company. In January 2011 the company licensed TALEN gene-editing technology …See details»
Cellectis - Crunchbase Company Profile & Funding
Cellectis may be growing as it has secured a significant investment from AstraZeneca, with reports indicating an investment of $245 million to bolster its gene therapy pipeline. Additionally, Cellectis has entered into a gene therapy …See details»
Cellectis - Crunchbase Company Profile & Funding
Cellectis is located in Göteborg, Vastra Gotaland, Sweden. Who are Cellectis 's competitors? Alternatives and possible competitors to Cellectis may include Gnubiotics Sciences , Syndivia , …See details»
Cellectis - LinkedIn
Cellectis | 43,056 followers on LinkedIn. Cellectis is developing life-changing product candidates to target and eradicate cancer cells. | Cellectis is a global clinical-stage biopharmaceutical …See details»
Cellectis Company Profile - Office Locations, Competitors, Revenue ...
Cellectis has 5 employees across 3 locations and $798 k in annual revenue in FY 2023. See insights on Cellectis including office locations, competitors, revenue, financials, executives, …See details»
Cellectis Company Profile: Overview and Full News Analysis
Cellectis, a company based in Ile-de-France, is a leader in gene editing technology, specifically leveraging its flagship technology, TALEN®, to create CAR T therapies for cancer patients. …See details»
Cellectis - businessabc.net
Sep 7, 2024 Cellectis is developing “off-the-shelf” CAR T-cell treatments meant to work for any person who has certain types of blood cancer.Most CAR-T therapies under development as of 2017 involved taking T-cells from the person with cancer and applying gene therapy to those cells to activate them to attack the person's cancer; an autologous cell therapy approach.See details»
Cellectis - Org Chart, Teams, Culture & Jobs - The Org
View Cellectis' up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. This is an unverified company page.See details»
Cellectis - Company Profile & Staff Directory - ContactOut
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to …See details»
Cellectis - Products, Competitors, Financials, Employees, …
Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise …See details»
Company: Cellectis - CRISPR Medicine
Cellectis develops next generation allogeneic CAR-T cell therapies using its proprietary Transcription activator-like effector nuclease (TALEN) technology. The company has multiple …See details»
Corporate Presentation - Cellectis
Cellectis is a clinical-stage biopharmaceutical company developing the Next-Generation CAR T-Cells to Cure Cancer.See details»
Cellectis Company Profile 2025: Stock Performance & Earnings
Cellectis General Information Description. Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and …See details»
Press Release Distribution and Management - GlobeNewswire
NEW YORK, 05 nov. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie …See details»
Cellectis - VentureRadar
" Cellectis leverages its leadership in gene editing through its flagship technology, TALEN®, which allows the company to create CAR T therapies to bring new hope to cancer patients through broadly available, off-the-shelf therapies. TALEN® has been successfully used in the clinic to solve key challenges with allogeneic CAR T including protection from Graft vs. Host Disease, …See details»
Cellectis S A : Corporate Presentation - January 2025
6 days ago Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of …See details»
Our Mission - Cellectis
2005: Breakthrough: Cellectis enables the industrial production of nucleases. Cellectis research teams provide proof of the in vivo efficacy of meganucleases, the molecular "scissors" that …See details»